Efficacy and Safety of Osteobiologics for Lumbar Spinal Fusion
Journal of Bone and Joint Surgery · 2025
DOI: 10.2106/jbjs.24.01205 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Bone and Joint Surgery, 2025. Verfasst von Luca Ambrosio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit of Orthopaedic and Trauma Surgery, Faculty of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Rome, Italy. Hauptthemen laut MEDLINE: Spinal Fusion, Lumbar Vertebrae, Bone Transplantation, Bone Morphogenetic Protein 2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Lumbar spinal fusion (LSF) is a common surgical procedure for treating lumbar degenerative conditions. The use of osteobiologics to enhance fusion has emerged as a promising alternative to address the limitations of autologous iliac crest bone graft (AICBG), but their comparative efficacy and safety remain unclear. This systematic review and network meta-analysis (NMA) aimed to assess the fusion rates, safety profiles, and clinical outcomes of the use of osteobiologics in LSF.
Methods
PubMed/MEDLINE and Scopus databases were searched for randomized controlled trials (RCTs) comparing different osteobiologics to AICBG in LSF. Data on fusion rates, complications, pain, disability, blood loss, operative time, and length of stay (LOS) were extracted. The risk of bias was evaluated using the Cochrane Risk of Bias-2 tool, and the certainty of evidence was assessed using the GRADE framework. The NMA was performed using a frequentist random-effects model to compare the efficacy and safety of various osteobiologics, along with associated perioperative and clinical outcomes.
Results
Forty-three RCTs including a total of 3,823 patients were identified. The use of rhBMP-2 (recombinant human bone morphogenetic protein-2) significantly improved fusion rates (odds ratio [OR]: 3.71; 95% confidence interval [CI]: 2.59 to 5.32; p < 0.0001) and reduced complications (OR: 0.30; 95% CI: 0.13 to 0.68; p < 0.0001) compared with AICBG, with moderate certainty of the evidence. Other osteobiologics, including ABM/P-15 (anorganic bone matrix/15-amino acid peptide fragment) and allograft, demonstrated reduced complication rates, although the quality of the evidence was low to very low. No significant differences were observed for pain, disability, or LOS. The use of rhBMP-2, autologous local bone, and silicate-substituted calcium phosphate was associated with decreased operative time, with rhBMP-2 additionally associated with lower intraoperative blood loss.
Conclusions
Use of rhBMP-2 was associated with significantly higher fusion and lower complication rates compared with AICBG, as well as decreased operative time and blood loss. Other osteobiologics may also offer benefits, but the supporting evidence is low-quality and limited by the notable underrepresentation of these materials in the published literature. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Unit of Orthopaedic and Trauma Surgery, Faculty of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Rome, Italy.
- Operative Research Unit of Orthopaedic and Trauma Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Department of Orthopedic Surgery, Tokai University School of Medicine, Isehara, Japan.
- Center for Musculoskeletal Innovative Research and Advancement (C-MiRA), Tokai University Graduate School, Isehara, Japan.
- Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Orthopaedics, Government Medical College, Karur, India.
ORCID-Profile: Luca Ambrosio, Jordy Schol, Shota Tamagawa, Sathish Muthu, Daisuke Sakai, Rocco Papalia, Gianluca Vadalà, Vincenzo Denaro
Zitieren
APA
Ambrosio, L., Schol, J., Tamagawa, S., Muthu, S., Sakai, D., Papalia, R., Vadalà, G., & Denaro, V. (2025). Efficacy and Safety of Osteobiologics for Lumbar Spinal Fusion. Journal of Bone and Joint Surgery. https://doi.org/10.2106/jbjs.24.01205
Vancouver
Ambrosio L, Schol J, Tamagawa S, Muthu S, Sakai D, Papalia R, et al. Efficacy and Safety of Osteobiologics for Lumbar Spinal Fusion. Journal of Bone and Joint Surgery. 2025. doi:10.2106/jbjs.24.01205
BibTeX
@article{Ambrosio2025,
author = {Ambrosio, Luca and Schol, Jordy and Tamagawa, Shota and Muthu, Sathish and Sakai, Daisuke and Papalia, Rocco and Vadalà, Gianluca and Denaro, Vincenzo},
title = {Efficacy and Safety of Osteobiologics for Lumbar Spinal Fusion},
journal = {Journal of Bone and Joint Surgery},
year = {2025},
doi = {10.2106/jbjs.24.01205}
}
EUVIMED